Clinical characteristics of and outcomes for patients with COVID-19 and comorbid lung diseases primarily hospitalized in a conventional pulmonology unit: A retrospective study

Respir Med Res. 2021 May:79:100801. doi: 10.1016/j.resmer.2020.100801. Epub 2020 Nov 12.

Abstract

Background: Scant data are currently available about a potential link between comorbid chronic lung diseases (CLD) and the risk and severity of the coronavirus disease 2019 (COVID-19) infection.

Methods: To describe the clinical characteristics of and outcomes for patients with COVID-19 infection, including patients with comorbid respiratory diseases, who have been primarily hospitalized in the pulmonology department of Strasbourg University Hospital, France. In this retrospective, single-center study, we included all confirmed cases of COVID-19 from March 3 to April 15, 2020. We then compared the symptoms, biological and radiological findings, and outcomes for patients with and without CLD.

Results: Of the 124 patients that were enrolled, the median age was 62 years, and 75 patients (60%) were male. Overall, 40% of patients (n=50) had preexisting CLD, including chronic obstructive pulmonary disease (COPD) (n=15, 12%) and asthma (n=19, 15%). Twenty-eight patients were transferred to the intensive care unit (ICU), and six patients died in our unit. CLD were not predictive of ICU hospitalization, but a significantly higher total mortality was observed (17.6% vs. 5.5%, P<0.05) in these patients.

Conclusions: Our results suggest the lack of an over-representation of CLD in COVID-19, representing 40% of patients in this cohort and even within a pulmonology department. CLD were not a risk factor for ICU management. However, a tendency to higher global mortality was observed in COVID-19 patients with CLD. Further studies are warranted to determine the risk of COVID-19 for patients with comorbid CLD.

Keywords: Asthma; COPD; COVID-19; Coronavirus; SARS-CoV-2.

MeSH terms

  • Aged
  • Anti-Bacterial Agents / therapeutic use
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Anticoagulants / therapeutic use
  • Antiviral Agents / therapeutic use
  • COVID-19 / epidemiology
  • COVID-19 / therapy*
  • Chronic Disease / epidemiology
  • Chronic Disease / therapy*
  • Comorbidity
  • Continuous Positive Airway Pressure
  • Diabetes Mellitus / epidemiology
  • Female
  • France / epidemiology
  • Heart Failure / epidemiology
  • Hospital Mortality
  • Hospitalization
  • Hospitals, University
  • Humans
  • Hydroxychloroquine / therapeutic use
  • Hypertension / epidemiology
  • Intensive Care Units
  • Lung Diseases / epidemiology
  • Lung Diseases / therapy*
  • Male
  • Middle Aged
  • Noninvasive Ventilation
  • Obesity / epidemiology
  • Oxygen Inhalation Therapy
  • Retrospective Studies
  • Sleep Apnea Syndromes / epidemiology
  • Smoking / epidemiology

Substances

  • Anti-Bacterial Agents
  • Antibodies, Monoclonal, Humanized
  • Anticoagulants
  • Antiviral Agents
  • Hydroxychloroquine
  • tocilizumab